Less than a year after buying a U.S. plant from AstraZeneca, Novartis’ biotech AveXis has it ready for production of Zolgensma, its gene therapy for spinal muscular atrophy. The new plant will help it get the treatment for the rare genetic disease to more patients. It also is building a plant in North Carolina that… Read More: Novartis’ AveXis opens Zolgensma plant in Colorado with 350 employees »
Call it a marriage gone bad. Novartis is expected to soon regain control of the Sandoz Boucherville sterile drug manufacturing site in Canada that it sold to Avara Pharmaceuticals last year. It turns out the relationship went bad almost as soon as it was consummated. The plant and development center that Novartis sold to Avara was… Read More: Novartis reclaims sterile products plant in Canada after sale goes… »
Six years after federal prosecutors first targeted Novartis for an alleged kickback scheme involving $ 10,000 dinners and fishing trips for doctors, signs pointed to the Swiss drugmaker finally having its day in court. Now, it looks like that may not happen. Novartis could be approaching a billion-dollar settlement with the U.S. government as part… Read More: Novartis could settle for $1B as part of federal kickback… »
(Reuters) – Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment. The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January… Read More: Second death in Novartis gene therapy trials under investigation »